Qarziba Dinutuximab Application Scope

Qarziba (Dinutuximab) is indicated for the treatment of high-risk neuroblastoma in pediatric patients. It is primarily used as part of a combination therapy to improve outcomes for patients with neuroblastoma who are at high risk of recurrence or metastasis.

Dinutuximab is a monoclonal antibody that targets the GD2 antigen, which is expressed on the surface of neuroblastoma cells, facilitating the immune system’s ability to destroy cancer cells. It is often used after initial treatments such as chemotherapy and surgical resection to reduce the risk of recurrence.

Qarziba Dinutuximab Characteristics

Ingredients:
- Active ingredient: Dinutuximab (a humanized monoclonal antibody)
- Excipients: Includes sodium chloride, water for injection, and other stabilizing agents.
Properties:Dinutuximab targets GD2, a cell surface antigen highly expressed on neuroblastoma cells. It works by activating the immune system through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death to eliminate tumor cells.
Specification:Available as an intravenous solution for infusion, typically in 10 mg/5 mL vials.
Storage:
- Store at 2°C to 8°C (36°F to 46°F) and do not freeze.
- Protect from light.
Expiry Date:Typically has a shelf life of 24 months (check packaging for exact expiry dates).
Executive Standard:Meets regulatory standards set by FDA and EMA for monoclonal antibody therapies.
Approval Number:Specific approval details from FDA or other local health authorities.
Manufacturer:United Therapeutics or authorized manufacturers.

Guidelines For The Use Of Qarziba Dinutuximab

Dosage and Administration:

Initial dose is typically 17.5 mg/m² body surface area administered as an intravenous infusion over 4 hours once a day for 4 consecutive days every 4 weeks for up to 5 cycles.
Dosage may be adjusted based on patient tolerance and clinical response.

Adverse Reactions:

Common side effects include fever, chills, nausea, fatigue, hypotension, and rash.
Serious side effects may include neutropenia, neurotoxicity, severe allergic reactions, and capillary leak syndrome.

Medication Limitations

Contraindications:

Hypersensitivity to Dinutuximab or any component of the formulation.
Contraindicated in patients with severe neutropenia or active infections.

Precautions:

Monitoring of blood counts is necessary during treatment due to the potential for cytopenia.
Use with caution in patients with pre-existing neuropathy or cardiovascular conditions due to the risk of exacerbating these conditions.

Qarziba Dinutuximab Interactions

Drug Interactions: No significant drug-drug interactions have been identified in clinical trials. However, caution should be exercised when used with other immune-modulating agents or chemotherapy agents, as these can increase the risk of immune system-related adverse effects.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Drug Import and Export Wholesaler.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.